News Image

TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Provided By GlobeNewswire

Last update: Nov 12, 2024

Upcoming oral presentation for the ALLOHATM Phase 1 heme trial at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Read more at globenewswire.com

TSCAN THERAPEUTICS INC

NASDAQ:TCRX (2/21/2025, 8:00:01 PM)

After market: 2.1987 +0.03 (+1.32%)

2.17

-0.02 (-0.91%)



Find more stocks in the Stock Screener

Follow ChartMill for more